Biotech · Private company · Worcester, MA, US
Signablok, Inc.
Track this companyFree. Adds Signablok, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- New TREM-1 therapy for inflammatory bowel diseaseFiscal year 2026 · $353.3KNIH RePORTER 1R43DK148026-01 · fetched Nov 12, 2026
- First-in-class TREM-1 inhibitors for neovascular retinal diseasesFiscal year 2026 · $830.5KNIH RePORTER 5R44EY034015-03 · fetched Nov 12, 2026
- Novel medical countermeasure to mitigate potentially lethal acute radiation syndromeFiscal year 2025 · $155.9KNIH RePORTER 1R21AI193495-01 · fetched Nov 12, 2026
- TREM-1 therapy for the treatment of empyemaFiscal year 2025 · $458KNIH RePORTER 1R43HL174220-01A1 · fetched Nov 12, 2026
- First-in-class TREM-1 inhibitors for neovascular retinal diseasesFiscal year 2025 · $830.5KNIH RePORTER 4R44EY034015-02 · fetched Nov 12, 2026